AYTU BIOPHARMA INC (AYTU)
US0547548588 - Common Stock
Taking everything into account, AYTU scores 3 out of 10 in our fundamental rating. AYTU was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of AYTU have multiple concerns. AYTU has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year AYTU has reported negative net income.
AYTU had a positive operating cash flow in the past year.
AYTU had negative earnings in each of the past 5 years.
AYTU had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of AYTU (-13.71%) is better than 69.23% of its industry peers.
AYTU has a Return On Equity (-54.79%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.71% | ||
| ROE | -54.79% | ||
| ROIC | N/A |
ROA(3y)-37.85%
ROA(5y)-40.1%
ROE(3y)-107.26%
ROE(5y)-143.56%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 63.24%, AYTU is doing good in the industry, outperforming 68.21% of the companies in the same industry.
In the last couple of years the Gross Margin of AYTU has grown nicely.
The Profit Margin and Operating Margin are not available for AYTU so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.24% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.22%
GM growth 5Y7.48%
2. Health
2.1 Basic Checks
AYTU does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AYTU has been increased compared to 1 year ago.
AYTU has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AYTU has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -2.53, we must say that AYTU is in the distress zone and has some risk of bankruptcy.
AYTU's Altman-Z score of -2.53 is in line compared to the rest of the industry. AYTU outperforms 44.62% of its industry peers.
The Debt to FCF ratio of AYTU is 2.62, which is a good value as it means it would take AYTU, 2.62 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.62, AYTU belongs to the top of the industry, outperforming 91.28% of the companies in the same industry.
A Debt/Equity ratio of 0.49 indicates that AYTU is not too dependend on debt financing.
AYTU's Debt to Equity ratio of 0.49 is on the low side compared to the rest of the industry. AYTU is outperformed by 63.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 2.62 | ||
| Altman-Z | -2.53 |
ROIC/WACCN/A
WACC14.54%
2.3 Liquidity
AYTU has a Current Ratio of 1.11. This is a normal value and indicates that AYTU is financially healthy and should not expect problems in meeting its short term obligations.
AYTU has a worse Current ratio (1.11) than 85.64% of its industry peers.
A Quick Ratio of 0.91 indicates that AYTU may have some problems paying its short term obligations.
The Quick ratio of AYTU (0.91) is worse than 82.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.11 | ||
| Quick Ratio | 0.91 |
3. Growth
3.1 Past
AYTU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 91.60%, which is quite impressive.
AYTU shows a decrease in Revenue. In the last year, the revenue decreased by -6.72%.
Measured over the past years, AYTU shows a very strong growth in Revenue. The Revenue has been growing by 96.14% on average per year.
EPS 1Y (TTM)91.6%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q96.95%
Revenue 1Y (TTM)-6.72%
Revenue growth 3Y57.29%
Revenue growth 5Y96.14%
Revenue growth Q2Q-12.73%
3.2 Future
AYTU is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.67% yearly.
Based on estimates for the next years, AYTU will show a small growth in Revenue. The Revenue will grow by 3.05% on average per year.
EPS Next Y54.78%
EPS Next 2Y44.96%
EPS Next 3Y26.67%
EPS Next 5YN/A
Revenue Next Year-19.95%
Revenue Next 2Y-14.06%
Revenue Next 3Y-12.05%
Revenue Next 5Y3.05%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AYTU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 5.69, the valuation of AYTU can be described as very cheap.
Based on the Price/Forward Earnings ratio, AYTU is valued cheaply inside the industry as 96.92% of the companies are valued more expensively.
AYTU's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.49.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.69 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AYTU indicates a rather cheap valuation: AYTU is cheaper than 97.95% of the companies listed in the same industry.
98.46% of the companies in the same industry are more expensive than AYTU, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.65 | ||
| EV/EBITDA | 2.71 |
4.3 Compensation for Growth
AYTU's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AYTU's earnings are expected to grow with 26.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.96%
EPS Next 3Y26.67%
5. Dividend
5.1 Amount
AYTU does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AYTU BIOPHARMA INC
NASDAQ:AYTU (4/26/2024, 7:00:00 PM)
2.9043
+0.06 (+2.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap16.18M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.69 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.71% | ||
| ROE | -54.79% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.24% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.11 | ||
| Quick Ratio | 0.91 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)91.6%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y54.78%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-6.72%
Revenue growth 3Y57.29%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y